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Eicosanoids in exhaled air after non-specific challenge in patients with 
asthma
Abstract
Background: Histamine is used as a direct stimulus to measure airway responsiveness. This short-acting biogenic amine 
acts mainly on airway smooth muscle receptors causing bronchoconstriction and is used for the airway hyperresponsiveness 
assessment in asthmatic patients. In aspirin-induced asthma (AIA) special regulatory role of eicosanoids is postulated. 
The aim of the study was to assess the influence of histamine on a wide profile of eicosanoids measured in exhaled breath 
condensate (EBC) in AIA patients and asthmatics tolerating aspirin well (ATA).
Methods: The study population consisted of seventeen asthmatics. Ten of them were AIA patients. Eicosanoid concentrations 
in EBC were determined using gas chromatography/mass spectrometry or high-performance liquid chromatography/tandem 
mass spectrometry. Measurements were performed at baseline and following bronchial histamine challenge.
Results: Bronchial reactions were precipitated by histamine in all patients and accompanied only by decrease of leukotriene 
(LT) C4 and trans-LTC4 mean level. The AIA group was characterized by higher levels of cysteinyl leukotrienes, LTC4, and 
prostaglandin (PG) E2 in EBC at baseline, and decrease in EBC concentration of LTC4, trans-LTC4 and tetranor-PGE-M 
following histamine challenge. In the ATA group no significant changes in eicosanoids levels after histamine were noticed.
Conclusions: AIA patients present different baseline profile of EBC eicosanoids  in comparison to patients with ATA. 
Histamine administered locally during a bronchial challenge test may influence inflammatory mediators and thus trigger 
indirect effects in the respiratory tract. This response for histamine differentiates two studied phenotypes of asthma; only in 
the AIA group histamine precipitates alterations of the eicosanoid synthesis in the lungs.
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Introduction
Histamine is a short-acting biogenic amine which plays an 
important role in allergic inflammation. Mast cells and 
basophiles store large quantities of histamine, which is released 
during degranulation in response to immunologic and non-
immunologic stimuli [1]. Histamine elicits many biological effects 
acting through four types of histamine receptors located on 
cells of various types. These include airway smooth muscle 
cells provoking airflow obstruction and sensory fibers causing 
a reflex response that can induce bronchospasm. Histamine, 
beside methacholine, is used as a direct stimulus to measure 
airway responsiveness.
Airway hyperresponsiveness (AHR) is one of the clinical 
features of asthma. Its measurement is crucial for establishing 
the correct diagnosis [17]. The components of airway changes 
in asthma that contribute to AHR can be differentiated into 
two categories: airway remodeling and airway inflammation.
It has been suggested that the action of histamine particularly 
reflects the effect associated with contractility of airway smooth 
muscle, called a direct effect. To a lesser degree, histamine 
may affect airway inflammation, which is called an indirect 
effect. However, the role of histamine in direct and indirect 
effects has not been clearly established. There is a correlation 
between measurements of airway responsiveness and 
number of eosinophils, mast cells [13] and epithelial cells [4] 
in bronchoalveolar lavage fluid (BALF) in asthma. In our study, 
we focused on the indirect action of histamine by measuring 
mediators released from inflammatory cells into the lumen of 
the airways in response to this agent.
Eicosanoids, including prostaglandins and leukotrienes, are 
arachidonic acid metabolites which play an important role in 
chronic inflammation in asthma, especially in the pathogenesis 
of aspirin intolerant asthma (AIA). AIA is a distinct clinical 
syndrome which affects 5-10% of asthmatics and refers to 
the coexistence of hypersensitivity to non-steroidal anti-
inflammatory drugs, rhinosinusitis/nasal polyps, and asthma [30].
Prostaglandin (PG) E2 is the most abundant prostanoid in 
the lower respiratory tract, produced mainly by epithelial and 
airway smooth muscle cells. Multiple studies have shown that 
PGE2 attenuates bronchoconstriction, increases the relaxation 
of airway smooth muscles and inhibits mast-cell degranulation 
[26]. PGE2 activity is expressed not only by direct effect on 
bronchial smooth muscle relaxation but also as suppression 
of the inflammatory mediators releasing mainly by eosinophils 
and mast cells [32]. In AIA diminished level of PGE2 was found 
in nasal polyps [15], peripheral blood cells [27] and bronchial 
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fibroblasts [19]. On the contrary, PGD2, mast cell autacoid 
mediator, is a potent agonist for airway smooth muscle 
contraction.
The PGE2 and PGD2 mediators are chemically unstable 
and become rapidly converted, via 13,14-dihydro-15-keto-
PGE2 and 9α,11β-PGF2, respectively, into tetranor-PGE-M and 
tetranor-PGD-M. The latter stable metabolites are considered 
to be the markers of PGE2 and PGD2 systemic production. One 
of the ultimate dehydration product of PGD2 is 15-deoxy-
delta12,14-PGJ2, whose level increases under stress such as 
infection and inflammation.
The inflammatory process in asthma is strongly influenced 
by leukotriene driven pathways. Leukotriene (LT) C4, LTD4, LTE4 
are often called cysteinyl leukotrienes (CysLTs). Trans-LTC4 is 
an isomer of LTC4 [12]. The increased CysLTs level, which may 
be the result of chronic eosinophlic inflammation of upper 
and lower respiratory tract, is considered a hallmark of AIA. 
LTE4, the end-metabolite of CysLTs, is a reliable marker of 
leukotriene generation in the lung.
Eicosanoids are present in very low concentrations in body 
fluids and exhaled air. Exhaled breath condensate (EBC) is a 
non-invasive technique for monitoring airway inflammation 
in inflammatory diseases such as asthma. Mediators measured 
in EBC are believed to derive from epithelial lining fluid of 
the small airways and alveoli [10].
The aim of our study was to evaluate the changes in 
concentration of wide eicosanoid spectrum in EBC during 
asthmatic response following histamine inhalation. We used 
this non-specific agent to assess its influence on inflammation 
in the airways. The study was carried out in patients with AIA 
and aspirin-tolerant asthma (ATA). We wondered if clinically 
manifested bronchoconstriction was accompanied by any 
change in eicosanoids profile in EBC in asthmatics. To our 
knowledge, we are the first to perform such investigations. 
Material and methods
Study subjects
The study population consisted of 17 asthmatics: 10 AIA 
subjects and 7 ATA patients. The diagnosis of asthma was 
established according to Global Initiative for Asthma 2011 
update [3]. Hypersensitivity to aspirin was confirmed by an 
oral aspirin provocation test within 12 months before the 
study. All ATA patients occasionally used aspirin without any 
adverse reactions.
Study participants had stable asthma without any 
exacerbation or respiratory tract infection during 6 weeks 
preceding the study. Their baseline FEV1 (forced expiratory 
volume in 1 second) was>70% of predicted value on the 
day of the study. The subjects were instructed to withdraw 
medications that decrease bronchial responsiveness before 
the histamine challenge. Inhaled corticosteroids were allowed 
at the dose ≤1500 μg of fluticasone equivalent per day. None 
of the patients was treated with systemic corticosteroids. 
The characteristics of the patients are presented in (Table 1).
All the subjects gave informed consent. The study was 
approved by the University Ethics Committee (KBET/44/B/2009). 
Study design
The single-blind bronchial challenge with histamine [20] began 
with inhalation of 5 breaths of placebo (saline). Histamine was 
inhaled every 10 minutes in increasing doses to the cumulative 
dose 2530 μg. FEV1 was measured before, 3 minutes after 
placebo inhalation and every 3 minutes after each dose of 
histamine. The challenge procedure was interrupted if FEV1 
decreased by more than 20% of the postsaline baseline value, 
or if the cumulative dose of histamine was reached. The 
cumulative dose of histamine causing bronchoconstriction 
(expressed as 20% fall in FEV1) was recorded as provocative 
dose (PD20). FEV1 was assessed after the last dose of histamine 
every 30 min., until FEV1 reached >80% postsaline baseline 
value.
In all study participants the histamine challenge was 
positive and EBC was collected within 30 min. before the 
challenge and during 30 min. after the time of appearance 
of bronchoconstriction which was restored spontaneously 
or was reversed by the inhalation of short-acting β2-agonist.
Lung function
Pulmonary function tests were performed using a flow-
integrating computerized pneumotachograph (Pneumoscreen, 
E. Jaeger, Germany).
Exhaled breath condensate 
EBC was collected according to the American Thoracic Society/ 
European Respiratory Society guidelines [10] using EcoScreen 
instrument (GmbH Hoechberg, Germany). During 20 minutes 
of tidal breathing, 2-3 ml of clear fluid was collected and 
immediately deep frozen. 
Biochemical assays
Concentration of eicosanoids in exhaled breath condensate 
was measured using gas chromatography/mass spectrometry 
(GC-MS) and high-performance liquid chromatography/
tandem mass spectrometry (HPLC-MS/MS) according to 
the methodology described elsewhere [24,25]. The results 
were reported in picograms per milliliter of EBC (pg/ml), or 
recalculated as picograms per microgram of palmitic acid 
content (pg/μg of PA) due to variable dilution by condensed 
water. 
Statistical analysis
Descriptive statistics were expressed as mean, standard 
deviation, median, lower and higher quartile (25% and 75% 
percentile). General linear model including repeated measures 
analysis of variance was used for multiple comparisons. 
Logarithmic transformation was used when needed as variance 
stabilizing transformation. Correlation between variables 
was estimated using the Spearman rank order correlations. 
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P-value<0.05 was assumed statistically significant.
 
Results
Clinical reactions
During histamine challenge none of the study subjects 
developed any symptoms after placebo inhalation. All 
participants responded to histamine. The only statistically 
significant differences in clinical characteristics between the 
subjects with AIA and with ATA were higher blood eosinophil 
count (p=0.03), and lower PD20 (p=0.008) in the AIA group 
(Table 1). 
Exhaled breath condensate concentration of eicosanoids
In the studied asthmatics, LTC4 and its isomer trans-LTC4 
proved to be the only measured eicosanoids for which EBC 
concentrations changed following the histamine challenge 
(Table 2). After the administration of inhaled histamine, their 
EBC concentration decreased significantly.
At baseline, the AIA group was characterized by higher 
CysLTs, LTC4, and PGE2 levels in EBC (Figure 1). Moreover, 
15-deoxy-delta12,14-PGJ2 row baseline concentration in 
EBC was increased in the AIA group (Table 3). Also, the 
assessment of changes in eicosanoids EBC concentration after 
administering histamine enabled us to observe differences 
between the AIA and ATA groups (Table 3). Following the 
histamine challenge, the levels of LTC4 (Figure 2), trans-LTC4 
(Figure 3) and tetranor-PGE-M (Figure 4) decreased in the AIA 
group. None of the measured eicosanoids changed its level 
after histamine in ATA group.
Correlation between clinical variables and EBC 
eicosanoids
Correlation analysis in subgroups was not performed due to 
the small number of subjects in the groups.
In all studied asthmatics a significant positive correlation 
between peripheral blood eosinophils and baseline PGE2 
(r=0.69) and LTC4 (r=0.61) concentration in EBC was observed. 
Baseline FEV1 was negatively correlated with post-challenge 
LTE4 (r=-0.63) and CysLTs (r=-0.67) EBC concentration. Pre-
challenge PGE2 correlated significantly with post-challenge 
one (r=0.60). No significant correlation was found between 
baseline and post-challenge EBC concentration within other 
AIA+ATA (n=17) AIA (n=7) ATA (n=10) p-value AIA vs. ATA
Age (yr.) 45.9±11.7 45.3±11.9 46.3±12.21 0.87
45 (35-56) 46 (34-57) 44(39-56)
Female / Male, no. 10/7 2/5 8/2 0.051
Duration of astma (yr.) 7.82±6.89 8.7±5.15 7.2±8.11 0.28
6(3-10) 6(5-14) 3.5(1-10)
Inhaled steroids (yes/no), no. 11/6 1/6 5/5 0.31
Inhaled steroids (  g of fluticasone 426.5±490.3 678.6±590.1 250±333.33 0.08
equivalent/d) 250(0-500) 500(250-1500) 125(0-500)
FEV1 baseline (% predicted) 89.64±10.58 86.79±10.06 91.64±11 0.37
89.56(82.77-94.44) 85.26(80.53-93.24) 94.25(82.77-97.2)
Total IgE (IU/mL) 100.9±149.4 69.44±30.35 122.86±194.35 0.46
52.4(23-92) 76(46.1-92) 40.5(20-94)
Skin prick test (positive/negative), no. 11/6 4/3 7/3 0.97
Blood eosinophil count (mm-3) 315.9±224.9 477.57±261.08 202.8±99.58 0.03*
284(200-339) 484(284-792) 223.5(121-285)
NHLBI asthma grade 1.29±0.47 1.4±0.53 1.2±0.42 0.35
1(1-2) 1(1-2) 1(1-1)
ACT 22.71±3.35 20.7±4.46 24.1±1.2 0.13
24(22-25) 22(16-25) 24.5(24-25)
PD20 (mg of histamine) 926.5±709.2 414.29±320.38 1285±692.07 0.008*
960(350-1100) 350(155-505) 1100(960-1850)
* statistical significance values are expressed as mean±SD and median with upper and lower quartile (25% and 75% percentiles) ACT: Asthma 
Control Test; AIA: aspirin-induced asthma, ATA: aspirin-tolerant asthma, FEV1: forced expiratory volume in 1 second, IgE: immunoglobulin 
E, IU: international unit, N.S: not significant, NHLBI: The National Heart, Lung, and Blood Institute; no., number; PD20: provocative dose; y, 
year.
Table 1. Clinical characteristics of the patients in the subgroups.
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baseline challenge p-value
LTB4 48.40 35.57 0.22
[pg/mL] (33.28-55.28) (24.37-52.09)
LTB4 74.64 70.42 0.71
[pg/μg of PA] (62.88-94.13) (42.01-119.02)
CysLTs 5.44 4.53 0.21
[pg/mL] (4.52-7.68) (3.79-6.42)
CysLTs 9.55 9.33 0.33
[pg/μg of PA] (8.32-13.72) (6.99-11.45)
LTC4 1.71 1.14 0.04*
[pg/mL] (1.21-2.14) (0.76-1.53)
LTC4 2.62 2.05 0.10
[pg/μg of PA] (2.13-3.44) (1.19-3.42)
trans-LTC4 1.24 0.62 0.02*
[pg/mL] (0.74-2.49) (0.53-1.11)
trans-LTC4 2.23 1.62 0.03*
[pg/μg of PA] (1.47-3.71) (0.75-2.35)
LTD4 1.09 0.93 0.64
[pg/mL] (0.77-1.23) (0.72-1.23)
LTD4 1.80 1.45 0.71
[pg/μg of PA] (1.12-2.25) (1.21-2.45)
LTE4 2.86 2.23 0.31
[pg/mL] (1.93-4.18) (1.62-3.40)
LTE4 5.22 4.33 0.76
[pg/μg of PA] (3.49-6.74) (3.09-6.18)
PGE2 1.99 2.05 0.76
[pg/mL] (1.44-2.75) (1.45-2.72)
PGE2 3.29 4.11 0.29
[pg/μg of PA] (2.73-4.65) (3.32-5.18)
13,14-dihydro-15-keto-PGE2 3.49 3.83 0.67
[pg/mL] (2.724.88) (2.76-4.86)
13,14-dihydro-15-keto-PGE2 5.03 6.34 0.59
[pg/μg of PA] (4.44-8.03) (4.77-9.60)
tetranor-PGE-M 21.36 15.76 0.41
[pg/mL] (12.20-38.80) (8.80-23.77)
tetranor-PGE-M 34.50 27.64 0.71
[pg/μg of PA] (25.82-49.50) (16.26-45.38)
PGD2 1.57 1.40 0.67
[pg/mL] (1.29-1.77) (1.00-1.85)
PGD2 2.12 2.09 0.24
[pg/μg of PA] (1.86-3.03) (1.94-3.49)
Table 2. Eicosanoids in asthmatic patients at baseline and following 
histamine challenge.
* statistical significance values are expressed as median with upper and lower 
quartile [25%-75% percentiles]
AIA: aspirin-induced asthma, ATA: aspirin-tolerant asthma, CysLTs: 
cysteinyl leukotrienes, GC-MS: gas chromatography/mass spectrometry, LT: 
leukotriene, PA: palmitic acid, PG: prostaglandin.
p-values :
I-AIA vs ATA at baseline.
II–AIA at baseline vs AIA post challenge.
III–ATA at baseline vs ATA post challenge.
13,14-dihydro-15-keto-PGD2 3.48 3.79 0.85
[pg/mL] (2.44-5.03) (2.44-4.90)
13,14-dihydro-15-keto-PGD2 6.27 5.88 0.40
[pg/μg of PA] (4.23-7.44) (4.56-8.71)
9a,11b-PGF2 0.17 0.11 0.14
[pg/mL] (GC-MS) (0.13-0.34) (0.09-0.26)
9a,11b-PGF2 0.28 0.22 0.42
[pg/μg of PA] (GC-MS) (0.22-0.65) (0.16-0.53)
15-deoxy-delta12,14-PGJ2 3.58 2.88 0.82
[pg/mL] (1.65-5.06) (2.34-4.98)
15-deoxy-delta12,14-PGJ2 5.54 6.87 0.60
[pg/μg of PA] (3.90-8.60) (5.10-8.13)
baseline challenge p-value
measured eicosanoids.
Discussion
At the beginning of the discussion section, some limitations 
of the study need to be noted. The main limitation consisted 
in relatively small patient populations. Another one was the 
lack of healthy control group. Such a group in the study could 
have helped us to better assess the production of eicosanoids 
in the respiratory system of the asthmatics. The study focused 
mainly on distinguishing between AIA and ATA in this respect.
We have noticed positive significant correlation between 
peripheral eosinophilia and baseline bronchial production 
of LTC4 in the studied patients.
The higher level of blood eosinophils was observed in the 
AIA group, which can probably be connected with decreased 
eosinophil apoptosis [33]. This observation is in line with 
previous reports [11,31]. The studied AIA subgroup was also 
characterized by increased baseline concentration of CysLTs 
and LTC4 in EBC. It is consistent with earlier study using 
immunoassay [2], although other studies using spectrometric 
methods did not demonstrate baseline overproduction of 
CysLTs [22] or LTC4 [24] in the airways in AIA. However, our 
observation is in line with researches assessing LTC4 level in 
induced sputum [18] and can be related to overexpression 
of LTC synthase (LTCS) in eosinophils [23] and bronchi [21] of 
asthmatics with aspirin hypersensitivity. Thus, overproduction 
Continuation of Table 2.
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AIA ATA p-value
baseline challenge baseline challenge I II III
LTB4 50.37 44.16 39.53 30.66 0.39 0.74 0.90
[pg/mL] (38.39-97.38) (24.37-59.99) (25.11-55.28) (11.44-47.89)
LTB4 83.00 78.53 71.11 60.56 0.56 0.93 1.00
[pg/μg of PA] (62.88-173.98) (42.01-119.02) (54.81-94.13) (30.56-120.39)
CysLTs 7.68 4.57 4.67 4.48 0.01* 0.07 0.99
[pg/mL] (5.62-14.46) (4.2-6.42) (3.52-5.44) (3.04-6.5)
CysLTs 13.72 9.85 8.46 8.6 0.02* 0.13 0.63
[pg/μg of PA] (9.55-19.94) 4.97-11.45) (6.19-10.66) (7.23-11.63)
LTC4 2.24 0.87 1.22 1.39 0.003* 0.001* 1.00
[pg/mL] (1.90-5.19) (0.54-1.43) (0.91-1.44) (0.76-1.77)
LTC4 3.68 1.83 2.15 2.60 0.01* 0.002* 0.88
[pg/μg of PA] (3.32-6.62) (0.83-2.26) (1.69-2.61) (1.89-3.71)
trans-LTC4 2.93 0.54 0.88 1.10 0.19 0.001* 0.83
[pg/mL] lg (0.60-4.72) (0.48-0.62) (0.74-1.37) (0.60-1.52)
trans-LTC4 4.81 0.85 2.01 2.27 0.19 0.001* 0.97
[pg/μg of PA] (1.07-5.88) (0.62-1.36) (1.47-2.60) (1.62-2.94)
LTD4 1.19 1.12 0.96 0.80 0.59 1.00 1.00
[pg/mL] (0.88-1.65) (0.83-1.76) (0.75-1.15) (0.72-1.07)
LTD4 1.80 1.84 1.96 1.42 0.91 0.99 0.99
[pg/μg of PA] (1.12-2.94) (1.28-2.72) (0.92-2.25) (1.20-2.16)
LTE4 4.18 2.80 2.31 1.79 0.22 0.58 0.97
[pg/mL] (3.18-7.62) (2.21-3.40) (1.49-2.86) (1.48-4.11)
LTE4 6.74 6.08 4.08 4.32 0.42 0.73 1.00
[pg/μg of PA] (5.22-9.50) (2.58-6.74) (3.17-5.79) (3.09-5.93)
PGE2 3.22 2.84 1.58 1.58 0.004* 0.96 1.00
[pg/mL] (2.23-4.13) (2.21-7.89) (1.24-1.94) (1.15-2.00)
PGE2 4.90 5.04 2.76 3.68 0.04* 0.80 0.90
[pg/μg of PA] (3.66-7.08) (4.11-11.56) (2.29-3.29) (2.33-4.34)
13,14-dihydro-15-keto-PGE2 3.82 3.83 2.73 3.46 0.83 0.91 1.00
[pg/mL] (3.49-4.88) (2.96-4.35) (2.26-5.65) (2.50-5.41)
13,14-dihydro-15-keto-PGE2 6.55 6.34 4.64 6.22 1.00 1.00 0.88
[pg/μg of PA] (4.65-8.03) (3.81-8.73) (3.32-15.98) (4.77-15.88)
tetranor-PGE-M 22.88 8.80 12.36 20.79 0.41 0.02* 0.23
[pg/mL] (16.87-38.80) (8.39-11.14) (7.97-38.89) (15.76-32.78)
tetranor-PGE-M 36.64 14.56 33.41 41.25 0.73 0.04* 0.10
[pg/μg of PA] (28.50-49.50) (13.00-19.42) (10.92-51.85) (27.64-87.07)
PGD2 1.48 1.48 1.58 1.23 0.99 0.99 0.90
[pg/mL] (1.29-1.77) (1.20-2.36) (1.28-1.86) (0.84-1.85)
PGD2 2.52 2.29 2.04 1.98 00.99 0.86 1.00
[pg/μg of PA] (1.89-3.03) (1.99-5.19) (1.76-4.80) (1.64-3.49)
13,14-dihydro-15-keto-PGD2 5.03 4.81 2.91 2.92 0.24 0.93 0.99
[pg/mL] (4.19-5.63) (3.52-4.92) (1.95-3.48) (2.16-4.21)
13,14-dihydro-15-keto-PGD2 7.18 6.64 4.97 5.88 0.82 1.00 0.67
Table 3. Eicosanoids in asthmatic patients at baseline and following histamine challenge in the subgroups.
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Figure 1. (a, b)Eicosanoids’ concentrations in EBC. AIA: aspirin 
induced asthma, ATA: aspirin tolerant asthma, EBC: exhaled breath 
condensate, post: after histamine, pre: before histamine; *, p<0.05.
AIA ATA p-value
baseline challenge baseline challenge I II III
Continuation of Table 3.
Figure 2. Changes in LTC4 concentration in EBC during bronchial 
challenge with histamine. AIA: aspirin induced asthma, ATA: aspirin 
tolerant asthma, EBC: exhaled breath condensate, LT: leukotriene, 
post: after histamine, pre: before histamine;  *, p<0.05.
Figure 3. Changes in trans-LTC4 concentration in EBC during 
bronchial challenge with histamine. AIA: aspirin induced asthma, 
ATA: aspirin tolerant asthma, EBC: exhaled breath condensate; trans-
LT: trans-leukotriene, post: after histamine, pre: before histamine; *, 
p<0.05.
* statistical significance values are expressed as median with upper and lower quartile [25%-75% percentiles] 
AIA: aspirin-induced asthma, ATA: aspirin-tolerant asthma, CysLTs: cysteinyl leukotrienes, GC-MS: gas chromatography/mass 
spectrometry, LT: leukotriene, PA: palmitic acid, PG: prostaglandin. 
p-values : 
I - AIA vs ATA at baseline. 
II – AIA at baseline vs AIA post challenge. 
III – ATA at baseline vs ATA post challenge.
[pg/μg of PA] (6.27-9.33) (5.44-9.86) (4.04-7.44) (3.90-8.71)
9a,11b-PGF2 0.22 0.10 0.16 0.12 0.88 0.91 0.52
[pg/mL] (GC-MS) (0.14-0.38) (0.08-0.71) (0.09-0.28) (0.09-0.14)
9a,11b-PGF2 0.30 0.20 0.24 0.23 0.99 0.99 0.85
[pg/μg of PA] (GC-MS) (0.25-0.65) (0.14-1.23) (0.18-0.70) (0.16-0.39)
15-deoxy-delta12,14-PGJ2 5.55 3.30 2.55 2.84 0.04* 0.43 0.41
[pg/mL] (4.24-8.36) (2.12-4.98) (1.43-3.58) (2.34-5.02)
15-deoxy-delta12,14-PGJ2 9.13 5.40 4.58 7.11 0.09 0.73 0.32
[pg/μg of PA] (5.28-10.66) (3.66-8.33) (2.52-5.84) (5.51-8.13)
7
Kaszuba et al. Hypersensitivity 2013, 
http://www.hoajonline.com/journals/pdf/2052-594X-1-4.pdf doi: 10.7243/2052-594X-1-4
Figure 4. Changes in tetranor-PGE-M concentration in EBC during 
bronchial challenge with histamine. AIA: aspirin induced asthma, 
ATA: aspirin tolerant asthma, EBC: exhaled breath condensate, PG: 
prostaglandin, post: after histamine, pre: before histamine; *, p<0.05.
of LTC4 observed in our study in AIA may be the result of both 
overexpression of LTCS and overrepresentation of eosinophils. 
Other important sources of eicosanoids could also be taken 
into consideration while explaining these observations, such 
as mast cells and airway epithelial cells, which were not 
assessed in the study.
The elevated level of PGE2 in EBC in the AIA group was a 
surprising finding. Other publications suggest diminished 
production of PGE2 in peripheral blood cells, upper airways 
and bronchial fibroblasts [30] in AIA. However the level of PGE2 
in BALF after placebo inhalation was higher in patients with 
AIA [28]. Increased production of PGE2 by basophil-enriched 
leukocytes in AIA patients has also been reported [8].
Bronchoconstriction appeared in both groups, which 
probably is an effect of direct histamine action on airway 
smooth muscle via histamine receptors. Interestingly, the 
level of PD20 was much lower in AIA than in ATA group. It may 
indicate more severe bronchial inflammation in asthmatics 
sensitive to aspirin. The elevated levels of CysLTs, LTC4, PGE2 
and 15-deoxy-delta12,14-PGJ2 in EBC of the AIA patients can 
be observed in our study as the result of such a condition. 
This state can be mirrored also in reported more severe 
clinical course of AIA, although differences between studied 
subgroups in clinical parameters are not statistically significant.
During histamine challenge, we noticed a decrease in 
EBC concentration of LTC4 and its isomer only in AIA group 
without significant changes in the levels of the other cysteinyl 
leukotrienes (assessed separately or totally). In a previous 
study, we showed that during bronchial challenge with 
specific agent=aspirin=the concentration of LTC4 decreased 
also only in AIA group. In that study in both groups, despite 
increase of LTE4 level, the total CysLTs concentration in EBC 
remained unchanged [16]. However, in many studies the 
levels of CysLTs was increased in AIA subjects following 
aspirin challenge in various biological samples [6,7,9,14,29]. 
Our previous and present observations may be explained 
by enhanced transformation of LTC4 via LTD4 to stable LTE4. 
Secondly, inflammatory mediators, such as LTE4, are released 
and act mainly across the distance of a few micrometers [5] 
on adjacent cells and, to a lesser extent, are excreted into 
the lumen of bronchi, so their measurement in EBC might 
be biased. The difference between LTC4 and LTE4 in terms of 
excretion into the bronchial lumen needs further exploration.
It is difficult to explain decreased concentration of tetranor-
PGE-M in EBC after histamine during bronchial challenge. 
Our observation may suggest diminished synthesis of PGE2 
under the influence of histamine, or what is less probable, 
decreased metabolism of this prostanoid.
Conclusions
The aim of this study was to assess the indirect effect of locally 
administrated stimulus on lower airways by measuring wide 
profile of eicosanoids released to the bronchi and present 
in EBC during the bronchial histamine challenge. In our 
study we demonstrated that histamine triggers not only 
direct but also indirect effects in respiratory tract causing 
both bronchoconstriction and alterations in the eicosanoid 
synthesis in the lungs. We demonstrated for the first time 
changes in exhaled eicosanoids in asthmatics after inhalation 
of histamine. This indirect action of histamine let us to reveal 
discrepancies in asthmatic inflammation between subjects 
with hypersensitivity to aspirin and tolerating aspirin well.
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